OP06: The influence of different prednisolone tapering algorithms on the effectiveness of infliximab in patients with Ulcerative Colitis – A real-world cohort studyECCO'22Year: 2022
Authors: Ovesen, P.D.(1);Ilvemark, J.F.K.F.(1);Attauabi, M.(1);Seidelin, J.B.(1);
(1)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;
OP07: Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trialECCO'22Year: 2022
Authors: Schreiber, S.(1);Feagan, B.(2,3);Peyrin-Biroulet, L.(4);Vermeire, S.(5);Faes, M.(6);Harris, K.(7);Oortwijn, A.(7);Daniele, P.(8);Patel, H.(6);Danese, S.(9,10);
(1)Kiel University, Department of General Internal Medicine, Kiel, Germany;(2)Alimentiv, Inc., London, Canada;(3)London Health Sciences Centre- Western- Western University, Division of Gastroenterology, London, Canada;(4)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;(5)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(6)Galapagos, Nv, Mechelen, Belgium;(7)Galapagos, Nv, Leiden, The Netherlands;(8)Cytel Health, Canada, Toronto, Canada;(9)University Vita-Salute, San Raffaele, Milan, Italy;(10)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;
OP08: The effects of maintenance therapy with upadacitinib on abdominal pain, bowel urgency, and fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 U-ACHIEVE maintenance resultsECCO'22Year: 2022
Authors: Danese, S.(1);Tran, J.(2);D'Haens, G.(3);Rubin, D.T.(4);Aoyama, N.(5);Zhou, W.(2);James, B.(2);Yao, X.(2);SanchezGonzalez, Y.(2);Panaccione, R.(6);
(1)Gastroenterology and Endoscopy IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, n/a, Milano, Italy;(2)AbbVie Inc., n/a, North Chicago, United States;(3)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(5)Aoyama Medical Clinic, Department of Gastroenterology- Gastrointestinal Endoscopy and IBD Center, Kobe, Japan;(6)University of Calgary, Department of Gastroenterology and Hepatology, Calgary, Canada;
OP09: Proactive Therapeutic Drug Monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B studyECCO'22Year: 2022
Authors: Jørgensen, K.K.(1);Syversen, S.W.(2);Goll, G.L.(2); Bjørlykke, K.H.(1,3);Sandanger, Ø.(4);Sexton, J.(2);Brun, M.K.(2,3);Noraberg, G.(5);Ystrøm, C.M.(6); Seeberg, K.A.(7);Blomgren, I.M.(8);Torp, R.(9);Mørk, C.(10);Kvien, T.K.(2,3); Bolstad , N.(4);Haavardsholm, E.A.(2,3);Jahnsen, J.(1,3); The NOR-DRUM study group
(1)Akershus University Hospital, Dept. of Gastroenterology, Oslo, Norway;(2)Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway;(3)University of Oslo, Faculty of Medicine, Oslo, Norway;(4)Oslo University Hospital, Section of Dermatology, Oslo, Norway;(5)Hospital of Southern Norway Trust, Dept. of Gastroenterology, Arendal, Norway;(6)Innlandet Hospital Trust, Dept. of Medicine, Elverum, Norway;(7)Vestfold Hospital Trust, Dept. of Gastroenterology, Tønsberg, Norway;(8)Fonna Hospital Trust, Dept. of Gastroenterology, Haugesund, Norway;(9)Innlandet Hospital Trust, Dept. of Medicine, Hamar, Norway;(10)Akershus Dermatology Center, Dept. of Dermatology, Lørenskog, Norway;
OP10: Comparative efficacy of biologics for endoscopic healing of the ileum and colon in Crohn’s DiseaseECCO'22Year: 2022
Authors: Narula, N.(1);Wong, E.(1);Dulai, P.(2);Marshall, J.(1);Jairath, V.(3);Reinisch, W.(4);
(1)McMaster University, Department of Medicine Division of Gastroenterology, Hamilton, Canada;(2)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(3)Western University, Department of Medicine Division of Gastroenterology, London, Canada;(4)Medical University of Vienna, Department of Internal Medicine III Division of Gastroenterology and Hepatology, Vienna, Austria;
OP11: Expanded genome-wide association study of Inflammatory Bowel Disease identifies 174 novel loci and directly implicates new genes in disease susceptibilityECCO'22Year: 2022
Authors: Fachal, L.(1);the International IBD Genetics Consortium, O.B.O.(1);
(1)Wellcome Sanger Institute, Human Genetics, Hinxton, United Kingdom;on behalf of the International IBD Genetics Consortium
OP12: Segmental vs Total Colectomy for Crohn’s Disease of the colon in the biologic era. Results from the SCOTCH international, multicentric studyECCO'22Year: 2022
Authors: PellinoMD- PhD- FRCS- FEBS Coloproctology- FA, G.(1);Rottoli, M.(2);Mineccia, M.(3);Frontali, A.(4);Celentano, V.(5);Colombo, F.(6);Ardizzone, S.(7);Martí, M.(8);Espín-Basany, E.(8);Ferrero, A.(9);Panis, Y.(10);Poggioli, G.(11);Sampietro, G.M.(12);
(1)Università degli Studi della Campania @Luigi Vanvitelli@, Department of Advanced Medical and Surgical Sciences, Naples, Italy;(2)Alma Mater Studiorum University of Bologna- Sant’Orsola – Malpighi Hospital, Surgery of the Alimentary Tract- Department of Medical and Surgical Sciences-, Bologna, Italy;(3)Ospedale Mauriziano “Umberto I”, Division of General and Oncologic Surgery-, Torino, Italy;(4)Hôpital Beaujon, Service de Chirurgie Colorectale Pôle des Maladies de l'Appareil Digestif PMAD, Clichy, France;(5)Portsmouth Hospitals NHS Trust- University of Portsmouth, Colorectal Surgery, Portsmouth, United Kingdom;(6)“Luigi Sacco” University Hospital, Division of General Surgery-, Milano, Italy;(7)“Luigi Sacco” University Hospital, Division of Gastroentrology-, Milano, Italy;(8)Vall d'Hebron University Hospital, Colorectal Surgery, Barcelona, Spain;(9)Ospedale Mauriziano “Umberto I”., Division of General and Oncologic Surgery-, Torino, Italy;(10)Hôpital Beaujon., Service de Chirurgie Colorectale Pôle des Maladies de l'Appareil Digestif PMAD, Clichy, France;(11)Alma Mater Studiorum University of Bologna- Sant’Orsola – Malpighi Hospital, Surgery of the Alimentary Tract- Department of Medical and Surgical Sciences, Bologna, Italy;(12)ASST Rhodense- Rho Memorial Hospital, Division of General and HPB Surgery, Rho, Italy;
OP13: Modified 2-stage vs. 3-stage ileal pouch-anal anastomosis result in equivalent long-term functional outcomes and pouch survival: A matched-pair analysisECCO'22Year: 2022
Authors: HolubarMD- MS, S.(1);Prien, C.(1);Jia, X.(2);Liska, D.(1);Kessler, H.(1);Valente, M.(1);Lightner, A.(1);Gorgun, E.(1);Hull, T.(1);Steele, S.(1);
(1)Cleveland Clinic, Department of Colon & Rectal Surgery, Cleveland, United States;(2)Cleveland Clinic, Department of Quantitative Health Sciences, Cleveland, United States;
OP14: Interpreting genome-wide association studies of Inflammatory Bowel Disease through the lens of single-cell sequencingECCO'22Year: 2022
Authors: Krzak, M.(1);Taylor, L.(1);Alegbe, T.(1);Ghouraba, M.(1);Strickland, M.(1);Przybilla, M.(1);Noell, G.(1);Iyer, V.(1);Cheam, A.X.(2);Matte, J.(1);Parkes, M.(3);McIntyre, R.(1);Raine, T.(3);Anderson, C.(1);
(1)Sanger Institute, Genomics of inflammation and immunity, Hinxton, United Kingdom;(2)Cambridge University, UK Dementia Research Institute, Cambridge, United Kingdom;(3)Addenbrooke’s Hospital, Department of Gastroenterology, Cambridge, United Kingdom;
OP15: A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative ColitisECCO'22Year: 2022
Authors: Villanacci, V.(1);Parigi, T.L.(2,3);Del Amor, R.(4);Mesguer Esbrì, P.(4);Gui, X.(5);Bazarova, A.(6);Bhandari, P.(7);Bisschops, R.(8);Danese, S.(9);De Hertogh, G.(8);Ferraz, J.G.(10);Götz, M.(11);Grisan, E.(12);Hayee, B.(13);Kiesslich, R.(14);Lazarev, M.(15);Mandelli, G.(1);Monica, M.A.T.(1);Panaccione, R.(10);Parra-Blanco, A.(16);Pastorelli, L.(17);Rath, T.(18);Røyset, E.S.(19);Shivaji, U.(3);Tontini, G.E.(17);Vieth, M.(20);Zardo, D.(21);Ghosh, S.(22);Naranjo, V.(4);Iacucci, M.(3);
(1)ASST Spedali Civili- University of Brescia, Institute of Pathology, Brescia, Italy;(2)Humanitas Research Hospital, Department of Biomedical Sciences, Milano, Italy;(3)University of Birmingham, Immunology and Immunotherapy, Birmingham, United Kingdom;(4)Universitat Politécnica de Valéncia, Instituto de Investigación e Innovación en Bioingeniería- I3B, Valencia, Spain;(5)University of Washington School of Medicine, Department of Laboratory Medicine and Pathology, Seattle, United States;(6)University of Cologne, Institute for Biological Physics, Cologne, Germany;(7)Queen Alexandra Hospital, Department of Gastroenterology, Portsmouth, United Kingdom;(8)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(9)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(10)University of Calgary Cumming School of Medicine, Division of Gastroenterology and Hepatology, Calgary, Canada;(11)Klinikum Böblingen, Division of Gastroenterology, Böblingen, Germany;(12)London South Bank University, School of Engineering, London, United Kingdom;(13)King’s College Hospital, King’s Health Partners Institute of Therapeutic Endoscopy, London, United Kingdom;(14)Helios HSK Wiesbaden, Department of Gastroenterology, Wiesbaden, Germany;(15)Johns Hopkins Hospital, Division of Gastroenterology and Hepatology, Baltimore, United States;(16)University of Nottingham, Department of Gastroenterology, Nottingham, United Kingdom;(17)University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy;(18)University of Erlangen, Department of Gastroenterology, Nuremberg, Germany;(19)Norwegian University of Science and Technology, Department of Clinical and Molecular Medicine, Trondheim, Norway;(20)Friedrich-Alexander University, Institute of Pathology- Klinikum Bayreuth-, Nuremberg, Germany;(21)University Hospitals Birmingham NHS Trust, Department of Cellular Pathology, Birmingham, United Kingdom;(22)University College Cork, Department of Medicine, Cork, Ireland;
OP16: The first virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative ColitisECCO'22Year: 2022
Authors: Iacucci, M.(1);Cannatelli, R.(2);Parigi, T.L.(1,3);Buda, A.(4);Labarile, N.(5);Nardone, O.M.(6);Tontini, G.E.(7);Rimondi, A.(7);Bazarova, A.(8);Bhandari, P.(9);Bisschops, R.(10);De Hertogh, G.(10);Del Amor, R.(11);Ferraz, J.G.(12);Goetz, M.(13);Gui, X.(14);Hayee, B.(15);Kiesslich, R.(16);Lazarev, M.(17);Naranjo, V.(11);Panaccione, R.(12);Parra-Blanco, A.(18);Pastorelli, L.(19);Rath, T.(20);Røyset, E.S.(21);Vieth, M.(22);Villanacci, V.(23);Zardo, D.(24);Ghosh, S.(25);Grisan, E.(26,27);
(1)University of Birmingham, Immunology and Immunotherapy, Birmingham, United Kingdom;(2)ASST Fatebenefratelli Sacco, Department of Gastroenterology, Milan, Italy;(3)Humanitas Research Hospital, Department of Biomedical Sciences, Milano, Italy;(4)Ospedale di Feltre, Digestive Endoscopy, Feltre BL, Italy;(5)National Institue of Research @Saverio De Bellis@, Section of Gastroenterology II, Castellana Grotte, Italy;(6)Federico II University, Department of Gastroenterology, Naples, Italy;(7)University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy;(8)University of Cologne, Institute for Biological Physics, Cologne, Germany;(9)Queen Alexandra Hospital, Department of Gastroenterology, Portsmouth, United Kingdom;(10)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(11)Universitat Politécnica de Valéncia, Instituto de Investigación e Innovación en Bioingeniería- I3B, Valencia, Spain;(12)University of Calgary Cumming School of Medicine, Department of Gastroenterology, Calgary, Canada;(13)Klinikum Böblingen, Division of Gastroenterology, Böblingen, Germany;(14)University of Washington School of Medicine, Department of Laboratory Medicine and Pathology, Seattle, United States;(15)King’s College Hospital, King’s Health Partners Institute of Therapeutic Endoscopy, London, United Kingdom;(16)Helios HSK Wiesbaden, Department of Gastroenterology, Wiesbaden, Germany;(17)John Hopkins Hospital, Department of Gastroenterology, Baltimore, United States;(18)University of Nottingham, Department of Gastroenterology, Nottingham, United Kingdom;(19)IRCCS Policlinico San Donato, Department of Gastroenterology, Milan, Italy;(20)University of Erlangen, Department of Gastroenterology, Nuremberg, Germany;(21)Norwegian University of Science and Technology, Department of Clinical and Molecular Medicine, Trondheim, Norway;(22)Klinikum Bayreuth- Friedrich-Alexander University, Institute of Pathology, Erlangen-Nuremberg, Germany;(23)ASST Spedali Civili, Institute of Pathology, Brescia, Italy;(24)University Hospitals Birmingham NHS Trust, Department of Cellular Pathology, Birmingham, United Kingdom;(25)University of Cork, School of Medicine, Cork, Ireland;(26)London South Bank University- London- UK, School of Engineering, London, United Kingdom;(27)University of Padova, Department of Information Engineering, Padova, Italy;
OP17: Maintenance phase propensity score adjusted effectiveness and persistence at week-52 in biologic-naïve Ulcerative Colitis patients treated with vedolizumab or anti-TNF (VEDO IBD-study)ECCO'22Year: 2022
Authors: Plachta-Danielzik, S.(1);di Giuseppe, R.(2);Bokemeyer, B.(3);Efken, P.(4);Mohl, W.(5);Krause, T.(6);Hoffstadt, M.(7);Ehehalt, R.(8);Trentmann, L.(9);Schweitzer, A.(10);Jessen, P.(11);Franzenburg, S.(1);Hartmann, P.(4);Schreiber, S.(12);
(1)Kompetenznetz Darmerkrankungen, Studienabteilung, Kiel, Germany;(2)Kompetenznetz Darmerkrankungen, Statistics and Biometry, Kiel, Germany;(3)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis Centre, Minden, Germany;(4)Gastroenterology Practice, Gastroenterology, Minden, Germany;(5)Gastroenterology Practice, Gastroenterology, Saarbrücken, Germany;(6)Gastroenterology Practice, Gastroenterology, Kassel, Germany;(7)Gastroenterology Practice, Gastroenterology, Iserlohn, Germany;(8)Gastroenterology Practice, Gastroenterology, Heidelberg, Germany;(9)Gastroenterology Practice, Gastroenterology, Bremen, Germany;(10)Gastroenterology Practice, Gastroenterology, Münster, Germany;(11)Gemeinschaftspraxis im Medicum, Gastroenterology, Altenholz, Germany;(12)Clinic of General Internal Medicine I, University Hospital Schleswig-Holstein- Campus Kiel, Kiel, Germany;
OP18: Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s Disease: Results from the phase 2 DIVERGENCE 2 studyECCO'22Year: 2022
Authors: Reinisch , W.(1);Colombel , J.F.(2);D’Haens , G.R.(3);Rimola , J.(4);DeHaas-Amatsaleh , A.(5);McKevitt , M.(6);Ren , X.(6);Serone , A.(6);Schwartz , D.A.(7);Gecse , K.B.(3);
(1)Medical University of Vienna, Department of Internal Medicine and Gastroenterology, Vienna, Austria;(2)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(3)Amsterdam University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)Hospital Clinic of Barcelona, Inflammatory Bowel Disease Unit, Department of Radiology, Barcelona, Spain;(5)Galapagos, NV, Mechelen, Belgium;(6)Gilead Sciences, Inc., Foster City, United States;(7)Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology and Nutrition, Nashville, United States;
OP19: Classifying perianal fistulising Crohn’s Disease: An expert-consensus to guide decision-making in daily practice and clinical trialsECCO'22Year: 2022
Authors: Geldof, J.(1);Iqbal, N.(2);LeBlanc, J.F.(3);Sawyer, R.(4);Buskens, C.(5);Bemelman, W.(5);Gecse, K.(6);Lundby, L.(7);Lightner, A.L.(8);Danese, S.(9);Spinelli, A.(10);Carvello, M.(10);Faiz, O.(11);Warusavitarne, J.(11);Lung, P.(12);De Looze, D.(13);D’Hoore, A.(14);Vermeire, S.(15);Hart, A.(3);Tozer, P.(16);
(1)UZ Gent, Gastroenterology and Hepatology, Gent, Belgium;(2)St Mark’s Hospital and Academic Institute, Robin Phillips Fistula Research Unit-, London, United Kingdom;(3)St Mark’s Hospital and Academic Institute, IBD unit, London, United Kingdom;(4)St Mark’s Hospital and Academic Institute, patient representative, London, United Kingdom;(5)Amsterdam University Medical Center- Gastroenterology Endocrinology Metabolism Research Institute, Department of Surgery, Amsterdam, The Netherlands;(6)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)Aarhus University Hospital, Department of Surgery- Pelvic Floor Unit, Aarhus, Denmark;(8)Cleveland Clinic, Center for Regenerative Medicine and Surgery Colorectal Surgery Digestive Disease Institute Inflammation and Immunity Lerner Research Institute Center for Immunotherapy, Cleveland, United States;(9)Vita-Salute San Raffaele University- IRCCS Hospital San Raffaele, Milan, Italy;(10)Humanitas University- IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Milan, Italy;(11)St Mark’s Hospital and Academic Institute, Department of Colorectal Surgery, London, United Kingdom;(12)St Mark’s Hospital and Academic Institute, Radiology department, London, United Kingdom;(13)University Hospital Ghent, Department of Gastroenterology and Hepatology, Ghent, Belgium;(14)University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;(15)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(16)St Mark’s Hospital and Academic Institute- and Imperial College, Robin Phillips Fistula Research Unit- Department of Colorectal Surgery-, London, United Kingdom;
OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrixECCO'22Year: 2022
Authors: Constable, L.(1,2);Iqbal, N.(3,4);Cozzetto, D.(1);Hart , A.(3,4);Tozer, P.(3,4);Powell, N.(1);
(1)Imperial College London, Metabolism- Digestion and Reproduction, London, United Kingdom;(2)King's College London, Inflammation Biology, London, United Kingdom;(3)St Mark's Hospital and Academic Institute, Robin Phillips Fistula Research Unit, London, United Kingdom;(4)Imperial College London, Surgery and Cancer, London, United Kingdom;
OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumabECCO'22Year: 2022
Authors: Alexander, J.(1,2);Kennedy, N.(3,4);Ibraheim, H.(1,2);Anandabaskaran, S.(1,5);Saifuddin, A.(1,5);Castro Seoane, R.(1);Liu, Z.(1);Nice, R.(4,6);Bewshea, C.(4);D'Mello, A.(7);Constable, L.(1);Jones, G.R.(8,9);Balarajah, S.(1,2);Fiorentino, F.(10);Sebastian, S.(11,12);Irving, P.M.(13,14);Hicks, L.(1,2);Williams, H.(1,2);Kent, A.(15);Linger, R.(16);King, R.(16);Parkes, M.(16,17);Kok, K.(18);Patel, K.(19);Altmann, D.(20);Boyton, R.(21);Goodhand, J.(3,4);Hart, A.(5);Lees, C.(8,9);Ahmad, T.(3,4);Powell, N.(1,2);
(1)Imperial College London, Metabolism- Digestion & Reproduction, London, United Kingdom;(2)Imperial College Healthcare NHS Trust, Gastroenterology, London, United Kingdom;(3)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(4)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(5)St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom;(6)Royal Devon and Exeter NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;(7)Imperial College Healthcare NHS Trust, Medicine & Integrated Care, London, United Kingdom;(8)Western General Hospital - NHS Lothian, Gastroenterology, Edinburgh, United Kingdom;(9)The University of Edinburgh, Centre for Inflammation Research - The Queen’s Medical Research Institute, Edinburgh, United Kingdom;(10)Imperial College London, Department of Surgery and Cancer, London, United Kingdom;(11)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Hull, United Kingdom;(12)University of Hull, Hull York Medical School, Hull, United Kingdom;(13)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(14)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(15)King's College Hospital, Gastroenterology, London, United Kingdom;(16)University of Cambridge, NIHR Bioresource, Cambridge, United Kingdom;(17)Cambridge University Hospitals NHS Trust, Gastroenterology, Cambridge, United Kingdom;(18)Bart's Health NHS Trust, Gastroenterology, London, United Kingdom;(19)St George's Hospital NHS Trust, Gastroenterology, London, United Kingdom;(20)Imperial College London, Immunology and Inflammation, London, United Kingdom;(21)Imperial College London, Department of Infectious Disease, London, United Kingdom;
OP22: Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patientsECCO'22Year: 2022
Authors: Lin, S.(1,2);Kennedy, N.A.(1,2);Saifuddin, A.(3,4);Muñoz Sandoval, D.(5);Reynolds, C.J.(5);Seoane, R.C.(6);Kottoor, S.H.(4);Pieper, F.P.(5);Lin, K.M.(5);Butler, D.K.(5);Chanchlani, N.(1,2);Nice, R.(2,7);Chee, D.(1,2);Bewshea, C.(2);Janjua, M.(1,2);McDonald, T.J.(7);Sebastian, S.(8,9);Alexander, J.L.(4,10);Constable, L.(4);Lee, J.C.(11,12,13);Murray, C.D.(11);Hart, A.L.(3);Irving, P.M.(14,15);Jones, G.R.(16,17);Kok, K.B.(18,19);Lamb, C.A.(20,21);Lees, C.W.(16,22);Altmann, D.M.(6);Boyton, R.J.(5,23);Goodhand, J.R.(1,2);Powell, N.(4,10);Ahmad, T.(1,2); CLARITY IBD
(1)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom;(4)Imperial College London, Metabolism- Digestion and Reproduction, London, United Kingdom;(5)Imperial College London, Infectious Disease, London, United Kingdom;(6)Imperial College London, Immunology and Inflammation, London, United Kingdom;(7)Royal Devon and Exeter NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;(8)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Hull, United Kingdom;(9)University of Hull, Hull York Medical School, Hull, United Kingdom;(10)Imperial College Healthcare NHS Trust, Gastroenterology, London, United Kingdom;(11)Royal Free London NHS Foundation Trust, Gastroenterology, London, United Kingdom;(12)University of Cambridge, Cambridge Institute of Therapeutic Immunology and Infectious Disease- Jeffrey Cheah Biomedical Centre, Cambridge, United Kingdom;(13)The Francis Crick Institute, Genetic Mechanisms of Disease Laboratory, London, United Kingdom;(14)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(15)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(16)Western General Hospital- NHS Lothian, Gastroenterology, London, United Kingdom;(17)The University of Edinburgh, Centre for Inflammation Research- The Queen’s Medical Research Institute, Edinburgh, United Kingdom;(18)Royal London Hospital- Barts Health NHS Trust, Gastroenterology, London, United Kingdom;(19)Barts and the London School of Medicine- Queen Mary, Centre for Immunobiology- Blizard Institute, London, United Kingdom;(20)Newcastle upon Tyne Hospitals NHS Foundation Trust, Gastroenterology, Newcastle upon Tyne, United Kingdom;(21)Newcastle University, Translational & Clinical Research Institute- Faculty of Medical Sciences, Newcastle upon Tyne, United Kingdom;(22)University of Edinburgh, Institute of Genetic and Molecular Medicine, Edinburgh, United Kingdom;(23)Royal Brompton Hospital and Harefield Hospitals, Lung Division, London, United Kingdom;
OP23: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12ECCO'22Year: 2022
Authors: Dignass, A.(1);Rubin, D.(2);Bressler, B.(3);Huang, K.H.(4);Shipitofsky, N.(4);Germinaro, M.(4);Zhang, H.(4);Johanns, J.(4);Feagan, B.(5);Sandborn, W.(6);Sands, B.(7);Hisamatsu, T.(8);Lichtenstein, G.(9);Panes, J.(10);Allegretti , J.(11); QUASAR Investigators
(1)Agaplesion Markus Hospital, Department of Medicine, Frankfurt, Germany;(2)The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(3)University of British Columbia, Division of Gastroenterology, Vancouver, Canada;(4)Janssen Research & Development- LLC, Immunology, Spring House, United States;(5)Western University, Robarts Clinical Trials, Ontario, Canada;(6)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(7)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(8)Kyorin University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(9)University of Pennsylvania, Department of Medicine- Division of Gastroenterology, Philadelphia, United States;(10)Hospital Clínic de Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;(11)Brigham and Women’s Hospital Crohn’s and Colitis Center, Division of Gastroenterology- Hepatology and Endoscopy, Boston, United States;
OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 studyECCO'22Year: 2022
Authors: Danese, S.(1);Panaccione, R.(2);Rubin, D.T.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Panés, J.(7);Gonzalez, S.(8);Weisel, K.(8);Sahoo, A.(8);Frustaci, M.E.(8);Yang, Z.(8);Sandborn, W.J.(9);Afzali, A.(10);Hisamatsu, T.(11);Andrews, J.M.(12);Feagan, B.(13); on behalf of the GALAXI-1 investigators
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(2)University of Calgary, Inflammatory Bowel Disease Group, Calgary, Canada;(3)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(5)Medical University of Vienna, Div. Gastroenterology & Hepatology, Vienna, Austria;(6)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(7)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(8)Janssen Research & Development- LLC, Immunology, Spring House, United States;(9)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(10)The Ohio State University, Wexner Medical Center, Columbus, United States;(11)Kyorin University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(12)Royal Adelaide Hospital & University of Adelaide, Department of Gastroenterology & Hepatology, Adelaide, Australia;(13)Western University and Alimentiv Inc., Department of Gastroenterology, London, Canada;
OP25: Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trialsECCO'22Year: 2022
Authors: Ferrante, M.(1);Cao, Q.(2);Fujii, T.(3);Rausch, A.(4);Neimark, E.(5);Song, A.(6);Wallace, K.(6);Kligys, K.(7);Zhou, Q.(8);Kalabic, J.(9);Feagan, B.G.(10);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Sir Run Run Shaw Hospital- Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China;(3)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(4)British Hospital, Gastroenterology Department, Buenos Aires, Argentina;(5)AbbVie, Clinical Development, Worcester, United States;(6)AbbVie, Clinical Development, North Chicago, United States;(7)AbbVie, Medical Affairs, Mettawa, United States;(8)AbbVie, Statistics, North Chicago, United States;(9)AbbVie Deutschland GmbH & Co. KG, Clinical Development, Ludwigshafen, Germany;(10)Western University, Robarts Clinical Trials- Robarts Research Institute, London, Canada;